High frequency intravitreal ranibizumab treatment in exudative age-related macular degeneration

Session Details

Session Title: Free Paper Session 9: AMD III

Session Date/Time: Friday 08/09/2017 | 08:00-09:30

Paper Time: 08:36

Venue: Room 117

First Author: : C.Türksever SWITZERLAND

Co Author(s): :    C. Pruente   K. Hatz                          

Abstract Details

Purpose:

To study efficacy and safety of high frequency intravitreal ranibizumab in nAMD.

Setting:

Prospective investigator initiated trial in Vista Klinik, Switzerland.

Methods:

This clinical trial including 24 treatment naive patients with nAMD. Therapy was carried out at baseline, afterwards up to 2-weekly according to predefined retreatment criteria. The follow-up was weekly (0-6 month) and two-weekly (6-12 month) including SD-OCT. Predicting factors as well as structural and functional changes were evaluated. One patient was excluded from efficacy analysis (drop out).

Results:

Mean number of injections was 7.9±5.1. Half of patients (52%) required retreatment earlier than 4 weeks after baseline injection. BCVA (ETDRS letters) was improved from 67.8±9.5 to 70.3±12.2 (p=0.048) already at week 2. Central retinal thickness (CRT), intraretinal (IRF)- and subretinal fluid (SRF) were already significantly improved at week 1 (p=0.000; p=0.014; p=0.003), respectively. Baseline integrity of IS/OS line and ELM, respectively, was correlated with better baseline BCVA (p=0.02; p=0.006). Baseline integrity of ELM indicated better BCVA ( p=0.027) at month 12. A reduction of hyperreflective foci (HRF) at week 2 was associated with lower CRT (p=0.024) at month 12. Improvement in SRF at week 2 predicted BCVA improvement (p=0.041) at month 12. Greater range of fluctuation of CRT during 12 months led to lower BCVA (p=0.027) at month 12. No severe adverse events occured.

Conclusions:

High-frequency ranibizumab treatment in nAMD is safe and efficient. More than half of patients need the first retreatment earlier than 4 weeks. Structural improvement after ranibizumab starts at 1 week.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy